First and foremost, Spotlight Innovation works with entrepreneurs and teams with the vision and determination necessary to make significant impacts on the world’s greatest health challenges. We provide a high level of service to all stakeholders, and we build our relationships around long-term commitments.

Spotlight Innovation provides solutions for healthcare-focused companies commercializing healthcare intellectual property developed by major centers of academia in the United States.

The Company focuses on identifying, validating and acquiring/cooperating with early stage companies developing healthcare technologies including pharmaceuticals, devices and equipment, diagnostic products and healthcare IT.


Seed, Early, Startup

Development Role:

Spotlight Innovation engages proactively with our portfolio companies by providing oversight, strategic direction, serving on boards, and business development assistance. We drive our portfolio companies for all stakeholders, including entrepreneurs, management, investors and employees.

Disease Focus:


Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells. If the spread is not controlled, it can result in death. Cancer is caused by both external actors (tobacco, infectious organisms, chemicals, and radiation) and internal factors (inherited mutations, hormones, immune conditions, and mutations that occur from metabolism). Cancer is treated with surgery, radiation, chemotherapy, hormone therapy, immune therapy, and targeted therapy.
— Source: American Cancer Society, Cancer Facts & Figures 2014

Cancer Costs

The National Institutes of Health (NIH) estimates that the overall costs of cancer in 2009 were $216.6 billion: $86.6 billion for direct medical costs (total of all health expenditures) and $130.0 billion for indirect mortality costs (cost of lost productivity due to premature death).

“The rising costs of cancer care illustrate how important it is for us to advance the science of cancer prevention and treatment to ensure that we’re using the most effective approaches,” said Robert Croyle, Ph.D., director, Division of Cancer Control and Population Sciences, NCI.

The NIH estimates that cancers cost the United States an overall $264 billion in 2010. It is estimated that approximately $10.3 billion per year is spent in the United States on lung cancer treatment alone.

Based on growth and aging of the U.S. population, medical expenditures for cancer in the year 2020 are projected to reach at least $158 billion (in 2010 dollars), an increase of 27 percent over 2010, according to a National Institutes of Health analysis. If newly developed tools for cancer diagnosis, treatment, and follow-up continue to be more expensive, medical expenditures for cancer could reach as high as $207 billion, said the researchers from the National Cancer Institute (NCI), part of the NIH.
— Source: National Institutes of Health (NIH)

Cancer Market

In 2010, the global cancer market was valued at $54 billion, with forecasted Compound Annual Growth Rate (CAGR) growth to $81 billion by 2016. The seven major cancer markets (US, France, Germany, Italy, Spain, United Kingdom and Japan) represented ~79% of the 2010 global cancer market ($43 billion). The US dominated 2010 sales with a market share of 38.5% and the leading ten companies of the global cancer market represented 87.1% ($47 billion) of the total market.
—Source: The Cancer Market Outlook to 2016; Competitive landscape, market size, pipeline analysis, and growth opportunities, June 2011